Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Emerging uses for genomic information in drug discovery.

Literature DB >> 9420347

Emerging uses for genomic information in drug discovery.

S H Friend¹, A Oliff.

Abstract

Mesh：

Substances：
Antineoplastic Agents

Year: 1998 PMID： 9420347 DOI： 10.1056/NEJM199801083380211

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

Keyword Cloud
Cited

× No keyword cloud information.

12 in total

1. The future of hospitals.

Authors: C B Wilson
Journal: BMJ Date: 1999-11-13

2. Nature Biotechnology's academic spinouts of 2017.

Authors: Malorye Allison Branca; Ken Garber; Laura DeFrancesco
Journal: Nat Biotechnol Date: 2018-04-05 Impact factor: 54.908

3. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions.

Authors: Steven R Bartz; Zhan Zhang; Julja Burchard; Maki Imakura; Melissa Martin; Anthony Palmieri; Rachel Needham; Jie Guo; Marcia Gordon; Namjin Chung; Paul Warrener; Aimee L Jackson; Michael Carleton; Melissa Oatley; Louis Locco; Francesca Santini; Todd Smith; Priya Kunapuli; Marc Ferrer; Berta Strulovici; Stephen H Friend; Peter S Linsley
Journal: Mol Cell Biol Date: 2006-09-25 Impact factor: 4.272

4. Inhibition of ATM kinase activity does not phenocopy ATM protein disruption: implications for the clinical utility of ATM kinase inhibitors.

Authors: Serah Choi; Armin M Gamper; Jason S White; Christopher J Bakkenist
Journal: Cell Cycle Date: 2010-10-27 Impact factor: 4.534

5. BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage.

Authors: Dan-Dan He; Xue-Ying Shang; Na Wang; Guang-Xing Wang; Kun-Yan He; Lan Wang; Ze-Guang Han
Journal: Oncogene Date: 2022-01-11 Impact factor: 8.756

6. Vascular Endothelial Growth Factor Receptor-1 Is Synthetic Lethal to Aberrant {beta}-Catenin Activation in Colon Cancer.

Authors: Snehal Naik; Robin S Dothager; Jayne Marasa; Cory L Lewis; David Piwnica-Worms
Journal: Clin Cancer Res Date: 2009-12-15 Impact factor: 12.531

Emerging uses for genomic information in drug discovery.

1. The future of hospitals.

2. Nature Biotechnology's academic spinouts of 2017.

3. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions.

4. Inhibition of ATM kinase activity does not phenocopy ATM protein disruption: implications for the clinical utility of ATM kinase inhibitors.

5. BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage.

6. Vascular Endothelial Growth Factor Receptor-1 Is Synthetic Lethal to Aberrant {beta}-Catenin Activation in Colon Cancer.

Review 7. Exploiting synthetic lethal interactions for targeted cancer therapy.

8. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells.

9. Synthetic genetic targeting of genome instability in cancer.

10. Chemical genetic screening of KRAS-based synthetic lethal inhibitors for pancreatic cancer.